M e d ic in e, T h e J o h n R a d c l if f e H o s p ita l, O x f o rd, U n ite d K in g d o m, 3 S e rv ic e o f
|
|
- Emerald York
- 5 years ago
- Views:
Transcription
1 P/Q-type calcium channel antibodies, L amber t-e aton myasthenic syndr ome and sur v iv al in small cell lung cancer P.W. Wirtz, 1 B. L a n g, 2 F. G ra u s, 3 A.M.J.M. v a n d e n M a a g d e n b e rg, 1, 4 A. S a iz, 3 P.A. d e K o n in g G a n s, 4 A. T w ij n s tra 5 a n d J.J.G.M. V e rs c h u u re n 1 1 D e p a rtm e n t o f N e u ro l o g y, L e id e n U n iv e rs ity M e d ic a l C e n tre, L e id e n, th e N e th e rl a n d s, 2 D e p a rtm e n t o f N e u ro s c ie n c e s, We a th e ra l l I n s titu te o f M o l e c u l a r M e d ic in e, T h e J o h n R a d c l if f e H o s p ita l, O x f o rd, U n ite d K in g d o m, 3 S e rv ic e o f N e u ro l o g y, H o s p í ta l C l in ic, U n iv e rs ita t d e B a rc e l o n a, B a rc e l o n a, S p a in, 4 C e n tre f o r H u m a n a n d C l in ic a l G e n e tic s, L e id e n U n iv e rs ity M e d ic a l C e n tre, L e id e n, 5 D e p a rtm e n t o f N e u ro l o g y, U n iv e rs ity H o s p ita l M a a s tric h t, M a a s tric h t, th e N e th e rl a n d s J Neuroimmunol 2005;164:
2 Abstract To assess the survival impact of the presence of P/Q-type calcium channel antibodies in patients with small cell lung carcinoma ( SCLC), we examined the freq uency of the antibodies and Lambert-E aton myasthenic syndrome ( LE MS) in consecutive patients with SCLC, and in 3 0 patients with paraneoplastic cerebellar degeneration and SCLC, and studied their relation with survival. In both series, only patients with LE MS had a remark ably long survival, whereas presence of the antibodies without LE MS did not result in a better prognosis. 116
3 P/Q-type calcium channel antibodies Introduction Small cell lung carcinoma (SCLC) cells express P/Q-type (Ca v2.1) voltage-gated calcium channels (VGCCs), against which the majority of patients with the Lambert- Eaton myasthenic syndrome (LEMS) produce antibodies that are functionally active and responsible for the typical muscle weakness. 1 LEMS usually antedates the detection of SCLC and occurs in a small proportion of SCLC patients. 2,3 LEMS was associated with improved survival in patients with SCLC, indicating that in LEMS the immune response to the tumour might inhibit its growth, thereby increasing the survival. 4 A small subgroup of SCLC-patients had P/Q-type VGCC antibodies without clinical features of LEMS, but it is unknown if these patient have prolonged survival as well. 5,6 In a substantial number of SCLC patients with paraneoplastic cerebellar degeneration (PCD) no other antineuronal antibodies than P/Q-type VGCC antibodies are detected, half of which have no clinical evidence for LEMS. 7 In this study we examined the frequency of P/Q-type VGCC antibodies and clinical features of LEMS in 148 consecutive patients with SCLC, and in 30 patients with PCD and SCLC, and studied their relation with survival. M ate rial s and m e th ods Consecutive patients with SCLC From January to July 2 001, a cohort of 148 consecutive Dutch patients with a SCLC, proven by cytology or histology, whose serum could be obtained at the time of diagnosis, were collected in the University Hospital Maastricht. Initial staging of these patients by a pulmonologist was based on physical examination, routine blood and chemistry profile, chest radiography, CT of the chest, ultrasound of the abdomen, radionuclide bone scan, fiberoptic bronchoscopy, MRI of the brain, and bone marrow aspirate and biopsy. Limited disease was defined as tumour confined to one hemithorax, including the mediastinum, the ipsilateral or contralateral scalene, and supraclavicular lymph nodes. In extensive disease tumour was found beyond these sites. A neurologist saw all patients at the time of diagnosis. Other neurological consultations or diagnostic tests took place as required. From each patient with SCLC a serum sample, obtained before chemotherapy, was kept frozen at -7 0 C until analysis. Only two patients were still alive at the time of the analysis. No patients had been lost to follow-up. P atients with P CD and SCLC From the database in the Hospítal Clinic, Barcelona, we selected Spanish patients with the final diagnosis of PCD with SCLC. 7 These 30 patients presented with an isolated or clearly predominant cerebellar syndrome of unknown cause and developed SCLC. 117
4 Patients with paraneoplastic encephalomyelitis, which almost always have Hu antibodies, were excluded. The final outcome was obtained by interview with the referring physician. At the time of the analysis 20 patients were dead and seven had been lost the follow-up usually at the time of the tumour relapse (median one month, range 0-10 months). Diagnostic criteria for LEMS Diagnostic criteria for LEMS were the presence of P/Q-type VGCC antibodies, and clinical features (proximal muscle weakness, lowered tendon reflexes, dry mouth). Electromyography supported the diagnosis if it comprised a reduced resting compound muscle action potential amplitude that increased by > 100% following high-frequency repetitive nerve stimulation (RNS) or maximal voluntary contraction. A ntib ody testing All patients were tested retrospectively for P/Q-type VGCC antibodies and Hu antibodies, and patient characteristics, staging and survival were compared between P/Q-type VGCC antibody positive patients with LEMS, P/Q-type VGCC antibody positive patients without LEMS and P/Q-type VGCC antibody negative patients. To test for P/Q-type VGCC antibodies, an immunoprecipitation assay, using [ 125 I] - omega-conotoxin MVIIC, which binds to P/Q-type VGCC, was performed as described previously. 6 Antibody titer was expressed as picomoles of [ 125 I] -toxin binding sites precipitated per litre of serum (pm). Sera were considered positive when the titre was greater than 5 0 pm (3 SD above the mean of the healthy controls). To test for Hu antibodies, Western blots using purified HuD fusion protein were performed as described previously. 8 Statistical analy sis Comparison of two qualitative variables was performed with the student t-test, the Pearson Chi-square or the Fisher s exact test when appropriate. Survival was determined from the date of SCLC diagnosis to death. The relation of antibody status or LEMS and survival was analysed using Kaplan-Meier plots and the Log-rank test. Statistical analysis was performed using SPSS 10 (Statistical Product and Services Solutions, Chicago, IL). Results Consecutive Dutch patients with SCLC ( tab le) P/Q-type VGCC antibodies were found in 10 patients (7% ). Median antibody titre in these patients was pm (range 76 to 1301 pm). In four of these patients (2.7% of total) clinical signs of LEMS were found; in three of them RNS was obtained, which 118
5 P/Q-type calcium channel antibodies Table 1. Patient characteristics P/Q-type VGCC antibody positive negative LEMS No LEMS 148 consecutive patients with SCLC Number of patients Mean age at diagnosis of SCLC ± SD (years) 50± 8 a 61± 8 64± 9 Male sex (71%) Extensive disease (61%) Response Complete b (33%) Other (62%) No chemotherapy (6%) Median survival and 95%CI 24 (7-41) c 7 (5-9) 10 (9-11) (months) Hu antibody positive (%) (15%) 3 0 patients with PCD and SCLC Number of patients Mean age at diagnosis of SCLC ± SD (years) 63± 5 63± 10 64± 10 Male sex (88%) Extensive disease (44%) Median survival and 95%CI (months) 24 (0-50) 11 (6-16) 10 (2-18) Hu antibody positive (%) (38%) VGCC - voltage gated calcium channel; LEMS - Lambert-Eaton my as thenic s y ndrome; P CD - p araneop las tic cerebellar degeneration. a Comp ared to VGCC antibody negative p atients p = b D is ap p earance of all tumour mas s es detected in the initial s taging p rocedures. c Comp ared to VGCC antibody p os itive p atients w ithout LEMS p = confirmed the diagnosis LEMS in one patient (>100% increase in compound muscle action potential amplitude after maximum voluntary contraction), but not in the other two patients in whom RNS was performed after chemotherapy. One other anti- VGCC antibody positive patient had cerebellar ataxia, but no signs of LEMS and no Hu antibodies. P/Q-type VGCC antibody positive patients with LEMS, but not those without LEMS, were significantly younger at diagnosis of SCLC than patients without antibodies (p= 0.006). Although initial staging, response to therapy and survival in 119
6 antibody positive patients were not different from patients without antibodies, the four antibody positive patients with clinical evidence of LEMS had a median survival of 24.5 months (8, 24, 25 and 34 months), against only 10 months median survival in antibody negative patients (p=0.13), and only 7 months in antibody positive patients without LEMS (p=0.02) (Figure A). Hu antibody status had no relation with survival. Spanish patients with PCD and SCLC (table) In 30 patients with PCD and SCLC, 14 (47%) had P/Q-type VGCC antibodies. Of the antibody positive patients, five (36%) had clinical and RNS features consistent with LEMS. No differences in age at diagnosis of SCLC were found between the groups. The antibody positive patients with clinical evidence of LEMS had a median survival of 24 months against only 10 months in antibody negative patients (p=0.12), and only 11 months in antibody positive patients without LEMS (p=0.06) (Figure B). Discussion In this study, we found a remarkably long survival in patients with SCLC positive for P/Q-type VGCC antibodies, but only in patients with clinical signs of LEMS. This long survival was found in a cohort of consecutive patients with SCLC, as well as in an independent group of patients with SCLC and PCD. In the group of 148 consecutive Dutch patients with SCLC, we found P/Q-type VGCC antibodies in 7% and Hu antibodies in 16% of the patients. This is in line with a study in 200 patients with SCLC (5% and 18.5%), that showed no relation of the presence of either antibody with prognosis, but did not take into account the presence of clinical features of LEMS. 9 Our Dutch P/Q-type VGCC antibody positive patients with signs of LEMS indeed had a long survival. We studied a separate group of Spanish patients with SCLC and PCD, in which we could confirm these results, which seems to exclude a bias due to the retrospective nature of our study of the Dutch patients. In both groups of patients, over half of the patients with P/Q-type VGCC antibodies had no features of LEMS. Several studies found a low incidence of these antibodies (2-7%) in SCLC patients without paraneoplastic neurological syndromes.,6,10 One study found a frequency of 18%, but used a lower upper limit of the normal range (2S.D. instead of 3 S.D. above the mean for healthy controls). 5 The presence of P/Q-type VGCC antibodies in SCLC patients without LEMS suggests that not all P/Q-type VGCC antibodies are pathogenic at the site of the neuromuscular synapse. The VGCC antibody immunoprecipitation assay will also detect antibodies binding intracellular epitopes, explaining why these antibodies did not result in prolonged survival. The survival curves suggest that the antibody positive SCLC patients without LEMS even have a shorter survival than antibody negative 120
7 P/Q-type calcium channel antibodies Fig 1. Kaplan-Meier survival curves for A. 148 consecutive patients with small cell lung carcinoma (SCLC), and B. 30 patients with SCLC and paraneoplastic cerebellar degeneration. Curves are shown for P/ Q -type voltage gated calcium channel (V G CC) antibody positive patients with clinical evidence of LEMS (V G CC+ LEMS+ ), P/ Q -type V G CC antibody positive patients without LEMS (V G CC+ LEMS-) and P/ Q -type V G CC antibody negative patients (V G CC-LEMS-). Censored cases of surviving patients or patients lost to follow-up are indicated by a sq uare. 1,0,8 probabillity of survival,6,4 VGCC- LEMS- VGCC+ LEMS+ A.,2 0,0 0 VGCC+ LEMS ,0 survival in months probability of survival,8,6,4 VGCC+ LEMS+ B.,2 0,0 0 VGCC+ LEMS- 20 VGCC- LEMS survival in months 121
8 patients. Possibly, the aggressive tumour growth leads to increased tumour debris. The presentation of intracellular epitopes could result in a non-pathogenic anti-vgcc immune response. The younger age at diagnosis of patients with LEMS in our group of consecutive patients with SCLC is in line with our recent epidemiological survey showing that the mean age at diagnosis of SCLC was 10 years lower in SCLC patients with concurrent LEMS, suggesting that patients who present with SCLC at an earlier age are additionally more prone to develop LEMS. 3 Several but not all large series of SCLC patients report age as an independent prognostic factor, younger patients having favourable prognosis, but this is still a controversial issue. 11 Possibly, SCLC patients with younger age generally have an anti-tumour immune response that is stronger, and therefore more frequently complicated by LEMS. Acknowledgement This work was supported by the Prinses Beatrix Fonds. 122
9 P/Q-type calcium channel antibodies References 1. P i n t o, A, I w a s a, K, N e w l a n d, C, N e w s o m - D a v i s, J, L a n g, B. T h e a c t i o n o f L a m b e r t - E a t o n m y a s t h e n i c s y n d r o m e i m m u n o g l o b u l i n G o n c l o n e d h u m a n v o l t a g e - g a t e d c a l c i u m c h a n n e l s. M u s c l e N e r v e 2002; 25 : O N e i l l, J H, M u r r a y, N M F, N e w s o m - D a v i s, J. T h e L a m b e r t E a t o n m y a s t h e n i c s y n d r o m e. A r e v i e w o f 5 0 c a s e s. B r a i n 111; 1988: W i r t z, P W, N i j n u i s, M G, S o t o d e h, M, W i l l e m s, L N, B r a h i m, J J, P u t t e r, H, W i n t z e n, A R, V e r s c h u u r e n, J J ; D u t c h M y a s t h e n i a S t u d y G r o u p,. T h e e p i d e m i o l o g y o f m y a s t h e n i a g r a v i s, L a m b e r t - E a t o n m y a s t h e n i c s y n d r o m e a n d t h e i r a s s o c i a t e d t u m o u r s i n t h e n o r t h e r n p a r t o f t h e p r o v i n c e o f S o u t h H o l l a n d. J N e u r o l 2003; 25 0: M a d d i s o n, P, N e w s o m - D a v i s, J, M i l l s, K R, S o u h a m i, R L. F a v o u r a b l e p r o g n o s i s i n L a m b e r t - E a t o n m y a s t h e n i c s y n d r o m e a n d s m a l l - c e l l l u n g c a r c i n o m a. L a n c e t 1999; 35 3: L e n n o n, V A, K r y z e r, T J, G r i e s m a n n, G E, O ' S u i l l e a b h a i n, P E, W i n d e b a n k, A J, W o p p m a n n, A, M i l j a n i c h, G P, L a m b e r t, E H. C a l c i u m - c h a n n e l a n t i b o d i e s i n t h e L a m b e r t - E a t o n s y n d r o m e a n d o t h e r p a r a n e o p l a s t i c s y n d r o m e s. N E n g l J M e d 1995 ; 332: M o t o m u r a, M., L a n g, B., J o h n s t o n, I., P a l a c e, J., V i n c e n t, A., N e w s o m - D a v i s, J.,. I n c i d e n c e o f s e r u m a n t i - P / Q - t y p e a n d a n t i - N - t y p e c a l c i u m c h a n n e l a u t o a n t i b o d i e s i n t h e L a m b e r t - E a t o n m y a s t h e n i c s y n d r o m e. J N e u r o l S c i 1997; 14 7: G r a u s, F, L a n g, B, P o z o - R o s i c h, P, S a i z, A, C a s a m i t j a n a, R, V i n c e n t, A. P / Q t y p e c a l c i u m - c h a n n e l a n t i b o d i e s i n p a r a n e o p l a s t i c c e r e b e l l a r d e g e n e r a t i o n w i t h l u n g c a n c e r. N e u r o l o g y 2002; 5 9: D a l m a u, J, F u r n e a u x, H M, G r a l l a, R J, K r i s, M G, P o s n e r, J B. D e t e c t i o n o f t h e a n t i - H u a n t i b o d y i n t h e s e r u m o f p a t i e n t s w i t h s m a l l c e l l l u n g c a n c e r - - a q u a n t i t a t i v e w e s t e r n b l o t a n a l y s i s. A n n. N e u r o l. 1990; 27: M o n s t a d, S E, D r i v s h o l m, L, S t o r s t e i n, A, A a r s e t h, J H, H a u g e n, M, L a n g, B, V i n c e n t, A, V e d e l e r, C A. H u a n d v o l t a g e - g a t e d c a l c i u m c h a n n e l ( V G C C ) a n t i b o d i e s r e l a t e d t o t h e p r o g n o s i s o f s m a l l - c e l l l u n g c a n c e r. J. C l i n. O n c o l ; 22; M a s o n, W P, G r a u s, F, L a n g, B, H o n n o r a t, J., D e l a t t r e, J Y, V a l l d e o r i o l a, F, A n t o i n e, J C, R o s e n b l u m, M K, R o s e n f e l d, M R, N e w s o m - D a v i s, J, P o s n e r, J B, D a l m a u, J. S m a l l - c e l l l u n g c a n c e r, p a r a n e o p l a s t i c c e r e b e l l a r d e g e n e r a t i o n a n d t h e L a m b e r t - E a t o n m y a s t h e n i c s y n d r o m e. B r a i n 1997; 120: P a e s m a n s, M, S c u l i e r, J P, L e c o m t e, J, T h i r i a u x, J, L i b e r t, P., S e r g y s e l s, R, B u r e a u, G, D a b o u i s, G, V a n C u t s e m, O, M o m m e n, P, N i n a n e, V, K l a s t e r s k y, J. P r o g n o s t i c f a c t o r s f o r p a t i e n t s w i t h s m a l l c e l l l u n g c a r c i n o m a : a n a l y s i s o f a s e r i e s o f 763 p a t i e n t s i n c l u d e d i n 4 c o n s e c u t i v e p r o s p e c t i v e t r i a l s w i t h a m i n i m u m f o l l o w - u p o f 5 y e a r s. C a n c e r 2000; 89:
10 124
Chapter 8. P.W. Wirtz, 1 B.O. R o e p, 2 G.M.T h. S c h re u d e r, 2 P.A. v a n D o o rn, 3
HLA class I and II in Lambert-Eaton my asth enic sy ndrome w ith ou t associated tu mou r P.W. Wirtz, 1 B.O. R o e p, 2 G.M.T h. S c h re u d e r, 2 P.A. v a n D o o rn, 3 B.G.M. v a n E n g e l e n, 4
More informationDetection of paraneoplastic anti- neuronal antibodies
Detection of paraneoplastic anti- neuronal antibodies Dr. A. R. Karim Department of Neuroimmunology University of Birmingham, UK Presentation format Background Detection method Examples Conclusion These
More informationAUTOIMMUNE ENCEPHALITIS
AUTOIMMUNE ENCEPHALITIS Shruti Agnihotri, MD Assistant Professor Department of Neurology, UAB August 12, 2017 DISCLOSURES No financial disclosure Evolving evidence Page 2 OBJECTIVES Review the types of
More informationDoppler ultrasound of the abdomen and pelvis, and color Doppler
- - - - - - - - - - - - - Testicular tumors are rare in children. They account for only 1% of all pediatric solid tumors and 3% of all testicular tumors [1,2]. The annual incidence of testicular tumors
More informationRelapse of both small cell lung cancer and Lambert Eaton myasthenic syndrome after a 13 year disease free survival period
DOI 10.1186/s40880-016-0127-x Chinese Journal of Cancer CASE REPORT Open Access Relapse of both small cell lung cancer and Lambert Eaton myasthenic syndrome after a 13 year disease free survival period
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20412 holds various files of this Leiden University dissertation. Author: Niks, E.H. Title: Myasthenia gravis with antibodies to muscle-specific kinase
More informationLong term survival study of de-novo metastatic breast cancers with or without primary tumor resection
Long term survival study of de-novo metastatic breast cancers with or without primary tumor resection Dr. Michael Co Division of Breast Surgery Queen Mary Hospital The University of Hong Kong Conflicts
More informationCorrelation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW
Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,
More informationLONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL
LONG-TERM SURGICAL OUTCOMES OF 1018 PATIENTS WITH EARLY STAGE NSCLC IN ACOSOG Z0030 (ALLIANCE) TRIAL Stacey Su, MD; Walter J. Scott, MD; Mark S. Allen, MD; Gail E. Darling, MD; Paul A. Decker, MS; Robert
More informationTHORACIC MALIGNANCIES
THORACIC MALIGNANCIES Summary for Malignant Malignancies. Lung Ca 1 Lung Cancer Non-Small Cell Lung Cancer Diagnostic Evaluation for Non-Small Lung Cancer 1. History and Physical examination. 2. CBCDE,
More informationRare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital
E-Da Medical Journal 20;():-5 Original Article Rare Small Cell Carcinoma in Genitourinary Tract: Experience from E-Da Hospital Wei-Ting Kuo, I-Wei Chang2, Kevin Lu, Hua-Pin Wang, Tsan-Jung u, Victor C.
More informationSlide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology
Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new
More informationThe clinical DELTA-P score accurately. predicts small cell lung cancer in the. Lambert-Eaton myasthenic syndrome
CHAPTER 6 The clinical DELTA-P score accurately predicts small cell lung cancer in the Lambert-Eaton myasthenic syndrome MJ Titulaer 1,2, P Maddison 3, JK Sont 4, PW Wirtz 5, D Hilton-Jones 2, R Klooster
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationNeuroblastoma. Elizabeth Roberts. Data Coordinator CIBMTR Data Managers Mentor. Tandem Meeting February 18
Neuroblastoma Elizabeth Roberts Data Coordinator CIBMTR Data Managers Mentor Tandem Meeting February 18 Objectives Know what neuroblastoma is, how it is diagnosed, and how it is treated Complete form 2026:
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED
More informationHyponatremia in small cell lung cancer is associated with a poorer prognosis
Original Article Hyponatremia in small cell lung cancer is associated with a poorer prognosis Wenxian Wang 1, Zhengbo Song 1,2, Yiping Zhang 1,2 1 Department of Chemotherapy, Zhejiang Cancer Hospital,
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationTemporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
More informationAssociation of motor milestones and SMN2 copy and outcome in spinal muscular. atrophy types 0 4
jnnp-2016-314292 1 - SUPPLEMENTARY FILE - Methods and additional data on clinical characteristics and motor development Association of motor milestones and SMN2 copy and outcome in spinal muscular atrophy
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationSergio Bracarda MD. Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy
Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy Ninth European International Kidney Cancer Symposium Dublin 25-26
More informationamifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd
amifampridine 10mg tablet, as phosphate (Firdapse ) BioMarin UK Ltd SMC No.(660/10) 06 July 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationRevisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis
Jpn J Clin Oncol 1997;27(5)305 309 Revisit of Primary Malignant Neoplasms of the Trachea: Clinical Characteristics and Survival Analysis -, -, - - 1 Chest Department and 2 Section of Thoracic Surgery,
More informationThe effect of delayed adjuvant chemotherapy on relapse of triplenegative
Original Article The effect of delayed adjuvant chemotherapy on relapse of triplenegative breast cancer Shuang Li 1#, Ding Ma 2#, Hao-Hong Shi 3#, Ke-Da Yu 2, Qiang Zhang 1 1 Department of Breast Surgery,
More informationequally be selected on the basis of RE status of the primary tumour. These initial studies measured RE
Br. J. Cancer (1981) 43, 67 SOLUBLE AND NUCLEAR OESTROGEN RECEPTOR STATUS IN HUMAN BREAST CANCER IN RELATION TO PROGNOSIS R. E. LEAKE*, L. LAING*, C. McARDLEt AND D. C. SMITH$ From the *Department of Biochemistry,
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More informationThe role of cytoreductive. nephrectomy in elderly patients. with metastatic renal cell. carcinoma in an era of targeted. therapy
The role of cytoreductive nephrectomy in elderly patients with metastatic renal cell carcinoma in an era of targeted therapy Dipesh Uprety, MD Amir Bista, MD Yazhini Vallatharasu, MD Angela Smith, MA David
More informationPROCARE FINAL FEEDBACK
1 PROCARE FINAL FEEDBACK General report 2006-2014 Version 2.1 08/12/2015 PROCARE indicators 2006-2014... 3 Demographic Data... 3 Diagnosis and staging... 4 Time to first treatment... 6 Neoadjuvant treatment...
More informationImpact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?
Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis? Thomas André Ankill Kämpe 30.05.2016 MED 3950,-5 year thesis Profesjonsstudiet i medisin
More informationSupplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier
Supplementary Figure S1 Expression of mir-181b in EOC (A) Kaplan-Meier curves for progression-free survival (PFS) and overall survival (OS) in a cohort of patients (N=52) with stage III primary ovarian
More informationLUNG CANCER Incidence of major histologic types*
LUNG CANCER Incidence of major histologic types* 5% other Small-cell carcinoma Adenocarcinoma 15% Large-cell carcinoma Adapted from Ihde DC, et al. Cancer: Principles & Practice of Oncology. 5th ed. 1997.
More informationA Proposed Strategy for Treatment of Superficial Carcinoma. in the Thoracic Esophagus Based on an Analysis. of Lymph Node Metastasis
Kitakanto Med J 2002 ; 52 : 189-193 189 A Proposed Strategy for Treatment of Superficial Carcinoma in the Thoracic Esophagus Based on an Analysis of Lymph Node Metastasis Susumu Kawate,' Susumu Ohwada,'
More informationSupplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2
Supplementary Fig. 1: ATM is phosphorylated in HER2 breast cancer cell lines. (A) ATM is phosphorylated in SKBR3 cells depending on ATM and HER2 activity. Upper panel: Representative histograms for FACS
More informationValidation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer
Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationNeurologic Complications of Cancer. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge Ontario
Neurologic Complications of Cancer Dr. Kathryn Giles MD, MSc, FRCPC Cambridge Ontario Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,
More informationRatio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer
Original Article Ratio of maximum standardized uptake value to primary tumor size is a prognostic factor in patients with advanced non-small cell lung cancer Fangfang Chen 1 *, Yanwen Yao 2 *, Chunyan
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationUpdate on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 4: 10:00 AM - 10:45 AM San Francisco, CA October 23, 2009 Speaker: Bruce E. Johnson, MD Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationNeuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER
Neuromuscular Junction Testing ELBA Y. GERENA MALDONADO, MD ACTING ASSISTANT PROFESSOR UNIVERSITY OF WASHINGTON MEDICAL CENTER Objectives Neurophysiology Electrodiagnostic Evaluation Clinical Application
More informationM K pag 132. Neurology Clinic, Carol Davila University of Medicine and Pharmacy, Colentina Clinical Hospital, Bucharest, Romania c
M K pag 132 Mædica - a Journal of Clinical Medicine EDITORIALS Paraneoplastic neurological disorders M. COJOCARU, MD, PhD a ; Inimioara Mihaela COJOCARU, MD, PhD b ; Isabela SILOSI, MD, PhD c a Physiology
More informationAntibodies Main associated neurological syndromes Cancer. Subacute cerebellar ataxia. Ma2-Ab Limbic encephalitis Testicular
Auto-antibodies Antibodies Main associated neurological syndromes Cancer Hu-Ab Yo-Ab CV2-Ab Ri-Ab amphiphysin-ab Sensory neuronopathy Encephalomyelitis Chronic gastrointestinal pseudoobstruction Cerebellar
More informationManagement of Neck Metastasis from Unknown Primary
Management of Neck Metastasis from Unknown Primary.. Definition Histologic evidence of malignancy in the cervical lymph node (s) with no apparent primary site of original tumour Diagnosis after a thorough
More informationBone Metastases in Muscle-Invasive Bladder Cancer
Journal of the Egyptian Nat. Cancer Inst., Vol. 18, No. 3, September: 03-08, 006 AZZA N. TAHER, M.D.* and MAGDY H. KOTB, M.D.** The Departments of Radiation Oncology* and Nuclear Medicine**, National Cancer
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationLiving with. LEMS.com LAMBERT-EATON MYASTHENIC SYNDROME
PATIENT INFORMATION Living with LAMBERT-EATON MYASTHENIC SYNDROME You have received this leaflet as you have been diagnosed with Lambert-Eaton myasthenic syndrome, or LEMS. This leaflet will give you and
More informationSpecialist Referral Service Willows Information Sheets. Cancer in cats and dogs: Assessment of the patient
Specialist Referral Service Willows Information Sheets Cancer in cats and dogs: Assessment of the patient Cancer in cats and dogs: Assessment of the patient Cancer is common in human and veterinary medicine.
More informationUpdates on the Conflict of Postoperative Radiotherapy Impact on Survival of Young Women with Cancer Breast: A Retrospective Cohort Study
International Journal of Medical Research & Health Sciences Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(7): 14-18 I J M R
More informationMyasthenia gravis. David Hilton-Jones Oxford Neuromuscular Centre
Myasthenia gravis David Hilton-Jones Oxford Neuromuscular Centre SWIM, Taunton, 2018 Myasthenia gravis Autoimmune disease Nature of Role of thymus Myasthenia gravis Autoimmune disease Nature of Role of
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Mesothelioma
THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma [Based on WOSCAN SCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED WHEN PRINTED Document
More informationreports during treatment with 3,4-diamino pyridine (mean difference
nature publishing group Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study PW Wirtz
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationA Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia
A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia Gaurav Bahl, Karl Tennessen, Ashraf Mahmoud-Ahmed, Dorianne Rheaume, Ian Fleetwood,
More informationGUIDELINES FOR CANCER IMAGING Lung Cancer
GUIDELINES FOR CANCER IMAGING Lung Cancer Greater Manchester and Cheshire Cancer Network Cancer Imaging Cross-Cutting Group April 2010 1 INTRODUCTION This document is intended as a ready reference for
More informationPatient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
MOLECULAR AND CLINICAL ONCOLOGY 7: 1083-1088, 2017 Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival FARUK TAS
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationHong-Gyun Wu, M.D., Charn Il Park, M.D., S ung Whan Ha, M.D., and Il Han Kim, M.D.
J. Korean Soc Ther Radiol Oncol 1999;17(1):108 112 1) S ign ifica nce of S uprac lav ic ula r Lymph Node Invo lve me nt o n Dete rm inat io n of Clin ica l Stag ing fo r Tho rac ic Es o phagea l Ca rc
More informationClinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer. Cheol Min Kang 2018/04/05
Abstract No.: ABS-0075 Clinicopathological Factors Affecting Distant Metastasis Following Loco-Regional Recurrence of breast cancer 2018/04/05 Cheol Min Kang Department of surgery, University of Ulsan
More informationDiagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD. November 18, 2017
Diagnosis and Staging of Non-Small Cell Lung Cancer Carlos Eduardo Oliveira Baleeiro, MD November 18, 2017 Disclosures I do not have a financial interest/arrangement or affiliation with one or more organizations
More informationClinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients
Yonago Acta medica 2012;55:57 61 Clinicopathologic Characteristics and Prognosis of Gastric Cancer in Young Patients Hiroaki Saito, Seigo Takaya, Yoji Fukumoto, Tomohiro Osaki, Shigeru Tatebe and Masahide
More informationRSR RSR RSR RSR RSR. ElisaRSR AQP4 Ab RSR. Aquaporin-4 Autoantibody Assay Kit
To aid diagnosis of Neuromyelitis Optica (NMO) and NMO spectrum disorder (NMOSD) To confirm diagnosis before initial treatment of patients with demyelinating inflammatory disease NMO, NMOSD and AQP4 Elisa
More informationSaudi Journal of Medicine (SJM)
Saudi Journal of Medicine (SJM) Scholars Middle East Publishers Dubai, United Arab Emirates Website: http://scholarsmepub.com/ ISSN 2518-3389 (Print) ISSN 2518-3397 (Online) Overview of Non-Squamous Cell
More informationSMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary)
SMALL CELL LUNG CANCER Updated Feb 2017 by Dr. Doreen Ezeife (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Desiree Hao (Staff Medical Oncologist, University of Calgary) and Dr.
More informationNon-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data
ANTICANCER RESECH 26: 3175-3182 (2006) Non-small Cell Lung Cancer in the Young: A Retrospective Analysis of Diagnosis, Management and Outcome Data D. MAURI, G. PENTHEROUDAKIS, D. BAFALOUKOS, D. PECTASIDES,
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationOutcomes of patients with inflammatory breast cancer treated by breast-conserving surgery
Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.
More informationThe tumor, node, metastasis (TNM) staging system of lung
ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,
More informationResponse of Osteosarcoma to Chemotherapy in Scotland. Ewan Semple, 5 th Year Medical Student, University of Aberdeen
Response of Osteosarcoma to Chemotherapy in Scotland Ewan Semple, 5 th Year Medical Student, University of Aberdeen 1 Summary Introduction Osteosarcomas are the most common primary bone tumour and affect
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationProperties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.12.4921 Properties of Synchronous Versus Metachronous Bilateral Breast Carcinoma with Long Time Follow Up RESEARCH ARTICLE Properties of Synchronous Versus Metachronous
More informationR. A. Nout Æ W. E. Fiets Æ H. Struikmans Æ F. R. Rosendaal Æ H. Putter Æ J. W. R. Nortier
Breast Cancer Res Treat (2008) 109:567 572 DOI 10.1007/s10549-007-9681-x EPIDEMIOLOGY The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated
More informationSupplemental Figure S1. RANK expression on human lung cancer cells.
Supplemental Figure S1. RANK expression on human lung cancer cells. (A) Incidence and H-Scores of RANK expression determined from IHC in the indicated primary lung cancer subgroups. The overall expression
More informationAcute presentations of lung cancer. Dr Prina Ruparelia Respiratory consultant Cambridge University Hospital
Acute presentations of lung cancer Dr Prina Ruparelia Respiratory consultant Cambridge University Hospital The problem Incidence CADIAS report /NCIN Acute lung cancer presentations Future pathway developments
More informationA variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study
ORIGINAL ARTICLE A variation in recurrence patterns of papillary thyroid cancer with disease progression: A long-term follow-up study Joon-Hyop Lee, MD, Yoo Seung Chung, MD, PhD,* Young Don Lee, MD, PhD
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationSmall cell lung cancer (SCLC) is an aggressive malignancy
BRIEF REPORT Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers Sinead Cuffe, MD,* Teng Moua, MD,
More informationThe European LEMS Registry: Baseline Demographics and Treatment Approaches
Neurol Ther (2015) 4:105 124 DOI 10.1007/s40120-015-0034-0 ORIGINAL RESEARCH The European LEMS Registry: Baseline Demographics and Treatment Approaches Renato Mantegazza. Andreas Meisel. Joern P. Sieb.
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationCancer Cell Research 16 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Paraneoplastic cerebellar degeneration in patients with breast cancer: two case reports and literature review Xin Li 1, Yingjie Chen 1, Xiao
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/188/20915 holds various files of this Leiden University dissertation. Author: Flinterman, Linda Elisabeth Title: Risk factors for a first and recurrent venous
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationFollow-up investigations. Omgo E. Nieweg
Follow-up investigations Omgo E. Nieweg Systematic literature review follow-up investigations identify few patients with recurrence frequent false positive findings impact on survival unclear Nieweg, Surg
More informationOnly Estrogen receptor positive is not enough to predict the prognosis of breast cancer
Young Investigator Award, Global Breast Cancer Conference 2018 Only Estrogen receptor positive is not enough to predict the prognosis of breast cancer ㅑ Running head: Revisiting estrogen positive tumors
More informationAuthor's response to reviews
Author's response to reviews Title: Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationLife Science Journal 2014;11(7)
Life Science Journal 4;(7) http://www.lifesciencesite.com Impact of primary tumor resection on response and survival in metastatic breast cancer patients Enas. A. Elkhouly¹, Eman. A. Tawfik ¹, Alaa. A.
More informationSupplementary Materials
Supplementary Materials Supplementary figure 1. Taxonomic representation summarized at genus level. Fecal microbiota from a separate set of Jackson and Harlan mice prior to irradiation. A taxon was included
More informationTumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma
ONCOLOGY LETTERS 9: 125-130, 2015 Tumor necrosis is a strong predictor for recurrence in patients with pathological T1a renal cell carcinoma KEIICHI ITO 1, KENJI SEGUCHI 1, HIDEYUKI SHIMAZAKI 2, EIJI TAKAHASHI
More informationNEWER TESTS IN NEUROLOGY DR RAJESH V BENDRE HOD, IMMUNOCHEMISTRY METROPOLIS, MUMBAI
NEWER TESTS IN NEUROLOGY DR RAJESH V BENDRE HOD, IMMUNOCHEMISTRY METROPOLIS, MUMBAI The Central Nervous System was considered an Immunological Privileged Site Blood brain barrier (BBB) Proapoptotic molecules
More informationTime to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective Cohort Study
Cancer and Clinical Oncology; Vol. 6, No. 2; 2017 ISSN 1927-4858 E-ISSN 1927-4866 Published by Canadian Center of Science and Education Time to Start Adjuvant Systemic Treatment in Breast Cancer; a Retrospective
More information